PROMO!
First order? Get 10% OFF with this code: 1storder
Tesamorelin is a synthetic peptide analog of human growth hormone–releasing hormone (GHRH) that acts as a growth hormone–releasing factor analog.
Tesamorelin is a synthetic version of human growth hormone-releasing hormone (GHRH); it is derived from the 44-amino-acid GHRH sequence and has a trans-3-hexenoyl group attached to its N-terminus, a structural change which sets it apart from native GHRH and one that is related to its molecular stability and analytical identity.
In laboratory research Tesamorelin is mainly studied as a ligand of the growth hormone-releasing hormone receptor (GHRH-R). The GHRH-R belongs to the class B of G-protein-coupled receptors and mainly involves adenylyl cyclase and cAMP-dependent signalling as a result of receptor activation. These systems offer well-established experimental models for the investigation of peptide–receptor recognition, receptor activation and the downstream second-messenger pathways.
Tesamorelin can therefore be used in controlled research examining GHRH-R pharmacology, peptide structure–activity relationships, receptor signaling and the effects of N-terminal peptide modification on molecular behavior.
In order to characterise the research material, the Tesamorelin provided should be assessed in terms of its chemical form, molecular identity, purity and the analytical data specific to the batch. The Peptide Works Certificate of Analysis provided attached indicates that the material in question is Tesamorelin, with the CAS number 901758-09-6, a molecular weight of 5135 g/mol and a molecular formula containing an acetate group.
Tesamorelin is a synthetic peptide analogue consisting of 44 amino acids of the human growth hormone-releasing hormone (GHRH/GRF), the peptide chain is derived from the 44-amino-acid sequence of human GHRH, but it is distinguished by the presence of a trans-3-hexenoyl group attached to the tyrosine residue at the N-terminus, the six-carbon modification with the double bond at position 3 is an essential part of Tesamorelin's molecular identity.
The peptide has a leucinamide at its C-terminus and includes one methionine residue, which is the source of the sulphur atom in the molecular formula. Since there are no cysteine residues in the sequence, the molecule does not form intramolecular disulphide bonds derived from cysteine. As shown in the FDA substance record, the full 44-residue peptide sequence and its specified N-terminal structural modification are confirmed.
Tesamorelin can be prepared in the form of an acetate salt. In the case of the acetate form, the FDA documentation provides the molecular formula C₂₂₁H₃₆₆N₇₂O₆₇S · xC₂H₄O₂, where x stands for the amount of acetate associated with it, and states that the molecular weight, on a free-base basis, is about 5135 g/mol.
The attached Peptide Works COA similarly identifies the supplied material with an acetate-containing formula and a stated molecular weight of 5135 g/mol.
For laboratory characterization, the peptide sequence, N-terminal modification, chemical form, molecular identity and batch-specific analytical specifications should therefore be considered together.
Tesamorelin is being studied as a synthetic growth hormone-releasing hormone (GHRH) receptor agonist. The molecular mechanism of Tesamorelin can be examined using receptor-binding and cell-based signalling systems which are designed to examine the interactions between the GHRH receptor (GHRH-R) and the intracellular pathways involved upon receptor activation. In vitro evidence shows that Tesamorelin binds to and stimulates human GHRH receptors.
GHRH Receptor Interaction
The GHRH receptor is a class B G-protein-coupled receptor (GPCR). Tesamorelin's interaction with this receptor provides an experimental model for investigating peptide–receptor recognition and comparing the molecular behavior of synthetic GHRH analogs with endogenous GHRH.
cAMP-Dependent Signaling
The signaling through GHRH-R is mainly linked to the activation of Gs-proteins and adenylyl cyclase, which in turn leads to a rise in intracellular cyclic adenosine monophosphate (cAMP). This cAMP then takes part in the activation of protein kinase A (PKA) as well as of the downstream signaling elements. Tesamorelin has also been tested in cell assays that express the receptor, using the amount of cAMP produced as an indicator of GHRH-R activation.
Calcium and Downstream Signaling
Experimental research into GHRH-R signaling has additionally examined changes in intracellular calcium, CREB phosphorylation and other signaling pathways. These processes provide complementary molecular endpoints for investigating how receptor activation is translated into cellular responses. Some secondary pathways have been described for GHRH-R systems, although the cAMP-dependent pathway remains the principal signaling mechanism.
Structural Modification
Tesamorelin is different from native GHRH because of a trans-3-hexenoyl group attached to its N-terminal end. Research shows that this modification leads to greater peptide stability as compared with native human GHRH, which means that the structural change is relevant to investigations into peptide stability and structure–activity relationships.
To sum up, tesamorelin can be used as a well-defined molecular probe for the investigation of GHRH-R binding, GPCR signalling, second-messenger pathways, and peptide structure–activity relationships under controlled experimental conditions.
This summary reflects findings reported in published preclinical and in vitro research. The original studies supporting this information are listed in the references.
Tesamorelin is investigated as a defined ligand of the growth hormone-releasing hormone receptor (GHRH-R). In-vitro studies have shown that it binds to and stimulates human GHRH receptors, providing an experimental model for examining peptide–receptor recognition and receptor activation.
The GHRH receptor is mainly a G-protein-coupled receptor of the class B type, which is linked to Gs-dependent signaling. In laboratory models of this receptor system, adenylyl cyclase activation and the production of intracellular cAMP are used as molecular endpoints, enabling the activity of GHRH analogs to be examined under controlled conditions.
The structure of GHRH-R has been studied using cryo-electron microscopy in order to examine the molecular arrangement of the receptor and how it interacts with the GHRH-family of ligands. The models thus obtained throw light on the process of ligand recognition, the conformational changes of the receptor, and G-protein coupling within the entire class B GPCR family.
The fact that tesamorelin has an N-terminal trans-3-hexenoyl modification means that peptide stability is a key focus of laboratory studies. Research comparisons show that this modification results in greater stability when compared with native human GHRH and thus provides a useful model for investigating how changes to the N-terminal structure affect peptide degradation.
Studies using mass spectrometry have looked at tesamorelin under controlled in-vitro conditions to examine its susceptibility to proteolytic degradation; LC-HRMS/MS experiments showed that it has a considerable resistance to degradation in human plasma when compared to some other GHRH-related peptides, thus illustrating the way in which analytical techniques can be employed to investigate peptide stability and molecular integrity.
Tesamorelin may also be studied in conjunction with native GHRH and structurally altered GHRH analogs. Comparative research involving the receptor, structure and analytical aspects offers a basis for looking at how modifications to the structure of the GHRH peptide affect its interaction with the receptor, its signalling and molecular stability, without extending the laboratory results to therapeutic outcomes.
The molecular identity, peptide integrity, and chromatographic purity of Tesamorelin Peptide must be verified by analytical methods. Reverse-phase high-performance liquid chromatography (RP-HPLC) can be used to examine the purity by separating the main Tesamorelin component from any detectable peptide-related impurities. The FDA's chemistry documentation states that among the analytical specifications for Tesamorelin are HPLC identification and the measurement of both the individual and total peptide-related impurities.
Mass spectrometry, including MALDI-TOF MS or LC-MS, provides complementary molecular-identity information by comparing the observed molecular mass with the expected Tesamorelin mass. FDA characterization has additionally used amino-acid analysis, peptide mapping and circular dichroism to support structural identification.
More specialized LC-HRMS/MS methods can provide sequence-related information through peptide fragmentation and have been applied to Tesamorelin analytical research.
For research material, results should be assessed against the batch-specific Certificate of Analysis, with particular attention to identity, purity, chemical form and the analytical methods used.
Store Tesamorelin research material at 2–8°C in a tightly sealed container. Protect the material from moisture, light and excessive heat during storage.
During laboratory handling, minimize exposure to humidity and temperature fluctuations. Keep the container closed when not in use and avoid unnecessary exposure to ambient conditions. Because Tesamorelin contains a methionine residue, minimize exposure to conditions that may promote oxidation.
Tesamorelin is a synthetic peptide which is analogous to the naturally occurring human growth hormone-releasing hormone (GHRH/GRF); it has the 44-amino-acid GHRH structure but includes a specific modification at the N-terminal position.
Tesamorelin is based on the 44-residue sequence of human GHRH. Its principal structural distinction is the addition of a trans-3-hexenoyl group at the N-terminal tyrosine residue, while the C-terminal residue is leucinamide.
The N-terminal tyrosine of Tesamorelin carries a trans-3-hexenoyl group. FDA documentation describes this as a six-carbon chain containing a double bond at position 3 and identifies it as a defining structural feature of the molecule.
Tesamorelin is investigated as an agonist ligand of the growth hormone-releasing hormone receptor (GHRH-R). This receptor provides a defined experimental system for examining peptide–receptor binding, receptor activation and associated intracellular signaling.
Tesamorelin can be compared with other GHRH-related peptides when tested under controlled experimental conditions in order to investigate its proteolytic stability and molecular integrity. Research using LC-HRMS/MS revealed that there were no considerable degradation products of tesamorelin under the in-vitro plasma-incubation conditions that were reported, thus providing an analytical model for the study of peptide stability.
Methods including HPLC, mass spectrometry, amino-acid analysis, peptide mapping and circular dichroism can contribute to Tesamorelin characterization. These techniques provide complementary information concerning chromatographic purity, molecular identity and peptide structure.
Mass spectrometry is able to compare the molecular species that have been observed in an experiment with the molecular mass that was expected for Tesamorelin. Furthermore, tandem high-resolution MS can offer extra information relating to the sequence through characteristic peptide fragmentation patterns.
Batch-specific verification provides analytical information about the particular Tesamorelin material being supplied, rather than relying solely on its general chemical identity. The Certificate of Analysis and supporting analytical data should therefore be reviewed when assessing the stated identity, purity and chemical form of an individual batch.
Tesamorelin is provided strictly for laboratory research and scientific investigation only. The research material described on this page is not intended for human or animal consumption, administration, diagnostic, therapeutic, or veterinary use.
It is not offered as a drug, medicine, dietary supplement, or treatment. Nothing on this page is intended to diagnose, treat, cure, or prevent any disease or medical condition. All information provided is for laboratory research and scientific reference purposes only.
